
4th NORDIC PATHOLOGY MEETING (NPM) on HISTOLOGY & BIOMARKERS in NSCLC

- Patient selection & Clinical impact of targeted therapy

Clarion hotel, Arlanda, Sweden

2016, 21-22 January



Dear Colleagues;

We would like to invite you to the 4th Nordic Pathology Network Meeting.

The meeting is hosted under the auspices of and organized by Danish Lung Pathologists Group (DaLuPa), Danish Oncology Lung Cancer Group (DOLG), Swedish Molecular Pathology (SMP) Group, Swedish Society of Pathology, the Swedish Lung Cancer Study Group (SLUSG) and a Nordic Pathology Network steering committee.

It will take place at Clarion Hotel Arlanda, Sweden in January 21-22nd 2016.

<http://www.clarionarlanda.com/>

The objective of the meeting is to highlight the latest developments in NSCLC from diagnostics, biomarkers and biomarker based treatments point of view.

Plenary sessions will cover highlights from the Lung cancer meetings in ASCO 2015/WCLC 2015, The New WHO classification of lung cancers 2015, The latest news regarding genomic testing of NSCLC and last - by not least- immunotherapy from clinical as well as from pathological point of view. Furthermore, there will be country-wise break-out sessions.

Who should attend? Pathologists, Molecular biologists, Lung oncologists, Pulmonologists
Lung nurses and Chairmen of patient organizations. Residents as well as consulting doctors should attend the meeting.

We hope that this will be an interesting and productive meeting and look forward to see you at Clarion Hotel Arlanda (Stockholm) in January.

The meeting is sponsored by AstraZeneca, Boehringer Ingelheim, BMS, Eli Lilly, MSD, Novartis, Pfizer, Qiagen and Roche.

Looking forward to see you at Arlanda in January,

Birgit Guldhammer Skov and Jens Benn Sørensen

On behalf of the steering committee:

Fredrik Enlund, Simon Ekman, Hans Brunnström,
Kaisa Salmenkivi & Lars Helgeland

4th NORDIC PATHOLOGY MEETING (NPM) on HISTOLOGY &
BIOMARKERS in NSCLC

- Patient selection & Clinical impact of targeted therapy

4th NORDIC PATHOLOGY MEETING (NPM) on HISTOLOGY & BIOMARKERS in NSCLC

- Patient selection & Clinical impact of targeted therapy

Clarion hotel, Arlanda, Sweden

2016, 21-22 January

Objective and goal

The objective of the meeting is to highlight the latest developments in NSCLC from diagnostics, biomarkers and treatments.

Day 1

9.00-10.00 Registration and coffee

10.00 - 10.15 Introduction and welcome

10.15 - 10.45 Highlights from the Lung cancer meetings in ASCO 2015/WCLC 2015

10.45 - 11.15 New WHO classification of lung cancers 2015

11.15 - 11.45 Coffee break

11.45 - 12.15 Cytology in the diagnosis of lung cancer.

12.15 - 12.45 Discussion

13 -14 Lunch

14.00 - 14.30 Biomarkers for targeted therapy in NSCLC – current and in the future

14.30 - 15.10 Genomic testing in the Nordic countries

15.10 - 15.30 Coffee break

15.30 - 16.00 Circulating tumor DNA (cDNA for EGFR mutation testing: response/progression

16.00 - 16.30 Diagnosing DNA on diagnostic specimens versus in diagnosing in blood

16.30 - 18.30 Break-out session. Country-wise: “How to optimize testing (EGFR and ALK for the moment) regarding genomic testing of the right patients with the right test at the right time”, “PD-L1 test. Where are we to day?”

19.30 - Dinner

Lecturer

Birgit Guldhammer Skov

Simon Ekman

Keith Kerr

Birgit Guldhammer Skov and Keith Kerr

Odd Terje Brustugun

Birgit Guldhammer Skov, Lars Helgeland,
Hans Brunnström, Kaisa Salmenkivi

Boe Sørensen

Fredrik Enlund and Johan Botling

Birgit Guldhammer Skov, Lars Helgeland,
Hans Brunnström, Kaisa Salmenkivi

Day 2

08.30 - 09.30 Panel discussion from break-out sessions

Birgit Guldhammer Skov, Lars Helgeland,
Hans Brunnström, Kaisa Salmenkivi

09.30 - 10.15 Managed introduction of new therapies: Decision on new therapies and their accompanying screening methods

Sven-Åke Lööf

10.15 - 10.45 Coffee break

10.45 - 11.15 Immunotherapy from clinical point of view

Jens Benn Sørensen

11.15 - 11.45 Immunotherapy from pathology point of view

Keith Kerr

11.45 - 12.15 Discussion

12.30 - 13.30 Lunch

13.30 - 13.50 Next Generation Sequencing heterogeneity

Reinhard Büttner

13.50 - 14.10 Next Generation Sequencing – from a diagnostic perspective

Fredrik Enlund and Johan Botling

14.10 - 14.30 Next Generation Sequencing What to report to the clinicians?

Reinhard Büttner

14.30 - 14.45 Discussion

14.45 - 15.15 Future perspective in lung cancer regarding biomarkers

Reinhard Büttner

15.15 - 15.30 Summary and conclusion

Jens Benn Sørensen

REGISTRATION

[Follow this link to register](#) to the Nordic Pathology Meeting, Arlanda 2016

Deadline for registration, with the lower cost, is the 15th of October

Final deadline for registration is the 11th of December

Please note that your registration is binding.

Should you have any problems opening the registration link above, please send an e-mail to catharina@compass360.se.
Mark your email: Nordic Pathology Meeting Arlanda 2016